A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 Tat Antagonist in Patients With HIV Infection

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2008-08-04

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

To study the anti-HIV activity of the various doses of Ro 24-7429 monotherapy based on virologic and immunologic endpoints. To study the safety and tolerance of Ro 24-7429. To explore relationships between exposure to Ro 24-7429 and its metabolites and antiviral activity and drug toxicity. To determine a safe, tolerable, and active dose regimen of Ro 24-7429, and to make preliminary observations of Ro 24-7429 in combination with another antiretroviral nucleoside. The HIV genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The tat (transactivator of transcription of HIV) antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach for therapy of HIV infection.

CONDITIONS

Brief Title

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

Who Can Participate

Age: 12Years +

All Genders

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Chemoprophylaxis for P. carinii pneumonia, TB, and mucocutaneous candidiasis.
Methadone maintenance.
Hormonal contraceptives.

Patients must have:

HIV-1 seropositivity.
CD4 count 50 - 500 cells/mm3.
Life expectancy of at least 24 weeks.
Stable weight (+/- 2 kg) by 28 days prior to study entry (by history).

NOTE:

At least 50 percent of patients must be p24 antigen positive (>= 50 pg/ml).

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

Known or suspected hypersensitivity to benzodiazepines.
Presence of any malignancy other than basal cell carcinoma or limited cutaneous Kaposi's sarcoma (defined as no more than five lesions with no mucosal involvement).
Ongoing diarrhea, defined as more than 2 liquid stools per day.
History, physical exam, or laboratory results consistent with a subclinical AIDS-defining opportunistic infection.
Grade 2 or greater signs and symptoms of AIDS Dementia Complex.
Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease.

Concurrent Medication:

Excluded:

Chronic suppressive therapy for CMV, MAI, toxoplasmosis, cryptococcosis, cryptosporidiosis, coccidioidomycosis, and histoplasmosis.
ddC, ddI, AZT (except for control groups) or other experimental antiretrovirals or immunomodulating agents.
Other medications excluded from the study.

Patients with the following prior conditions are excluded:

History of serious adverse reactions to benzodiazepines.
History of intolerance to AZT at 600 mg/day or less or ddI at 400 mg/day or less.
History of unexplained fever, defined as a temperature of 38.5 deg C or greater with or without night sweats for more than 7 of the past 28 days.

Prior Medication:

Excluded:

Benzodiazepines within 14 days prior to study entry.

Active drug or alcohol abuse that would interfere with study compliance.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here